Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

See the 10 stocks » The strong performance was driven by the company's pair of semaglutide drugs ... severely limiting their adoption. While Novo Nordisk owns the market for now, a pill-based ...

Shares of Novo Nordisk (NYSE: NVO ... the 10 stocks » The strong performance was driven by the company's pair of semaglutide drugs, Wegovy and Ozempic. Of the full year's total sales of $40.5 ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too ... And the inclusion of the semaglutide drugs — Wegovy for weight loss and Ozempic for diabetes, as well as an older semaglutide drug, Rybelsus ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about ... having just had prices set for some of its insulin products in the past year. And the inclusion of the semaglutide drugs — Wegovy for ...